lobbying_activities: 2298867

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2298867	6598a85d-e699-466a-ab45-b581f92e0cf4	Q2	ALAN REUTHER	400618875	UAW RETIREE MEDICAL BENEFITS TRUST	2019	second_quarter	HCR	Implementation, Repeal and Replacement, and Improvement of ACA; Changes in Medicare Benefits and Financing; CMS initiatives on Part B and Part D drug prices; Insulin prices; measures to limit drug prices; drug price negotiation initiatives; drug patent abuses; drug advertising limits;drug price transparency; insurance market stabilization legislation; reinsurance programs; Medicare buy-in legislation; Medicare for America; surprise medical bills; CREATES Act; pay-for-delay agreements; Alexander-Murray health care legislation; FDA hearing on biosimilar insulin; repeal of Cadillac tax	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	18000		0	0	2019-07-02T15:02:18.140000-04:00